Literature DB >> 11786177

Synergistic inhibitory activity of alpha- and beta-LFA-1 peptides on LFA-1/ICAM-1 interaction.

H Yusuf-Makagiansar1, I T Makagiansar, Y Hu, T J Siahaan.   

Abstract

Interactions of cell-adhesion molecule LFA-1 and its ligand ICAM-1 play important roles during immune and inflammatory responses. Critical residues of LFA-1 for ICAM-1 binding are known to be in the I-domain of the alpha-subunit and the I-like domain of the beta-subunit. On the basis of our previous work demonstrating the inhibitory activity of I-domain cyclic peptide cLAB.L on LFA-1/ICAM-1 interaction, here we have explored the activity of I-like-domain peptide LBE on the binding mechanism of cLAB.L. LBE enhances cLAB.L binding to T-cells and epithelial cells. The adherence of T-cells to epithelial monolayers was suppressed by the two peptides. The addition of LBE to the monolayers prior to the addition cLAB.L produced a better inhibitory effect than the reverse procedure. LBE, but not cLAB.L, changes the ICAM-1 conformation, suggesting that LBE binds to ICAM-1 at sites that are distinct from these of cLAB.L and induces improved conformation in ICAM-1 for binding to cLAB.L.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11786177     DOI: 10.1016/s0196-9781(01)00546-0

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  9 in total

1.  Controlling ligand surface density optimizes nanoparticle binding to ICAM-1.

Authors:  Amir Fakhari; Abdulgader Baoum; Teruna J Siahaan; Khoi Ba Le; Cory Berkland
Journal:  J Pharm Sci       Date:  2010-10-04       Impact factor: 3.534

2.  ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells.

Authors:  Chuda Chittasupho; Sheng-Xue Xie; Abdulgader Baoum; Tatyana Yakovleva; Teruna J Siahaan; Cory J Berkland
Journal:  Eur J Pharm Sci       Date:  2009-02-27       Impact factor: 4.384

3.  Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor.

Authors:  Naoki Kobayashi; Paul Kiptoo; Hitomi Kobayashi; Rahmawati Ridwan; Stefan Brocke; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2008-08-03       Impact factor: 3.969

4.  cIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cells.

Authors:  Chuda Chittasupho; Prakash Manikwar; Jeffrey P Krise; Teruna J Siahaan; Cory Berkland
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

5.  Single-step grafting of aminooxy-peptides to hyaluronan: a simple approach to multifunctional therapeutics for experimental autoimmune encephalomyelitis.

Authors:  Joshua Sestak; Meagan Mullins; Laura Northrup; Sharadvi Thati; M Laird Forrest; Teruna J Siahaan; Cory Berkland
Journal:  J Control Release       Date:  2013-03-27       Impact factor: 9.776

Review 6.  Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases.

Authors:  Mario E G Moral; Teruna J Siahaan
Journal:  Curr Top Med Chem       Date:  2017       Impact factor: 3.295

Review 7.  Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases.

Authors:  Prakash Manikwar; Paul Kiptoo; Ahmed H Badawi; Barlas Büyüktimkin; Teruna J Siahaan
Journal:  Med Res Rev       Date:  2011-03-23       Impact factor: 12.944

8.  Mechanism of binding and internalization of ICAM-1-derived cyclic peptides by LFA-1 on the surface of T cells: a potential method for targeted drug delivery.

Authors:  Meagan E Anderson; Teruna J Siahaan
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

9.  Codelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitis.

Authors:  Joshua O Sestak; Bradley P Sullivan; Sharadvi Thati; Laura Northrup; Brittany Hartwell; Lorena Antunez; M Laird Forrest; Charlotte M Vines; Teruna J Siahaan; Cory Berkland
Journal:  Mol Ther Methods Clin Dev       Date:  2014-04-09       Impact factor: 6.698

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.